Optimization of Diarylthiazole B‐Raf Inhibitors: Identification of a Compound Endowed with High Oral Antitumor Activity, Mitigated hERG Inhibition, and Low Paradoxical Effect
Maurizio Pulici(Nerviano Medical Sciences), Marina Ciomei(Nerviano Medical Sciences), Antonella Isacchi(Nerviano Medical Sciences), Daniele Donati(Nerviano Medical Sciences), Rosita Lupi(Nerviano Medical Sciences), Wilma Pastori(Nerviano Medical Sciences), Elena Casale, Eduard Felder, Gabriella Traquandi(Nerviano Medical Sciences), Nicoletta Colombo(Nerviano Medical Sciences), Fabio Gasparri(Nerviano Medical Sciences), Alessandra Scolaro(Nerviano Medical Sciences), Enrico Pesenti, L. Corti(Nerviano Medical Sciences), Chiara Marchionni(Nerviano Medical Sciences), Michele Modugno(Nerviano Medical Sciences), Marina Fasolini(Nerviano Medical Sciences), Arturo Galvani(Nerviano Medical Sciences), Nadia Amboldi(University of Pavia)
Cited by 9
Related Papers
Discovery of drug mode of action and drug repositioning from transcriptional responses
|Proceedings of the National Academy of Sciences|2010|853
Entrectinib, a Pan–TRK, ROS1, and ALK Inhibitor with Activity in Multiple Molecularly Defined Cancer Indications
|Molecular Cancer Therapeutics|2016|317
Interaction of the anthracycline 4'-iodo-4'-deoxydoxorubicin with amyloid fibrils: inhibition of amyloidogenesis.
|Proceedings of the National Academy of Sciences|1995|205